



COMPANY UPDATE

Rating: **BUY**

Ticker: SINT

Price: \$2.79

Target: \$28
(from \$30)

SINTX Technologies, Inc.

Reports Q1. We believe biomedical commercialization ramp in 2025 to be positive for stock. Lowering P/T to \$28.

Reports Q1: SINTX recently (on May 15) reported its Q1 2025 (ending March) results. Revenue was \$0.4 million, compared with our and consensus estimates of \$0.6 – 0.9 million. Net loss was \$2.3 million or EPS of \$(1.29), compared with our and consensus estimates of \$(0.71) – (0.80). There was no Q1 guidance.

Operating expenses: Operating expenses were \$2.5 million (vs. \$1.9 million in Q4).

No guidance: Management did not provide forward guidance.

Adjusting 2025 estimates: We are adjusting our 2025 estimates for revenue to \$1.6 million, from \$3.6 million, and for EPS to \$(3.44) from \$(2.81).

Focused on silicon nitride commercialization: SINTX is focused on developing silicon nitride products for medical and non-medical products in collaboration with medical/non-medical products manufacturers. The company believes that silicon nitride has a superb combination of properties that make it ideally suited for many medical applications. The company is actively developing products with its OEM partners and have shipped prototype orders.

Exits TA&T market: In February 2025, the company sold its Technology Assessment and Transfer (TA&T) business to Tethon Corporation.

Agribiotech market: SINTX has formed a wholly-owned subsidiary that will have a dedicated management team focused on developing and commercializing agricultural and environmental technologies—SINTX Agribiotech, Inc. The global antimicrobial fertilizer and crop protection market is projected to grow significantly, reaching up to \$10 billion by 2030.

Large market potential: The company is aiming for wide commercial opportunities across medical and non-medical industries for silicon nitride.

Key catalysts expected in 2025: SINTX's goal in 2025 is to reach key technology and sales milestones including: 1) support CTL and drive further adoption of silicon nitride spinal fusion devices 2) develop commercial opportunities outside of spine 3) apply its silicon nitride technology platform to other OEM opportunities.

Cash balance: The company ended Q1 with \$7 million in cash and no debt. In Q1, the company raised ~\$5 million selling stock. We believe the company has enough cash into 2026.

New CEO: In April 2024, the company announced that B. Sonny Bal, MD, informed his intention to retire as President and CEO, effective on the company naming a replacement. In August 2024, the company appointed Eric Olson as CEO.

Positive high risks versus rewards: While we expect numerous silicon nitride products to be announced over the next year, there is still a long road to successful product commercialization. However, we believe the ~billion dollars market potentials presents a high reward for the risks.

Current valuation attractive: Maintaining our BUY rating, but lowering our 12-month price target to \$28 from \$30. This is based on a NPV analysis, representing significant upside from the current share price. We believe this valuation appropriately balances out the company's high risks with the company's high growth prospects and large upside opportunities.

Company Description

Based in Salt Lake City, UT, SINTX Technologies is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications.

United States
Healthcare

May 29, 2025

Edward Woo, CFA
(561) 327-9435
ewoo@ascendant.com

Stock Data

Exchange:	NasdaqCM
52-week Range:	\$1.71 – 8.60
Shares Outstanding (million):	3
Market cap (\$million):	\$8
EV (\$million):	\$1
Debt (\$million):	\$0
Cash (\$million):	\$7
Avg. Daily Trading Vol. (\$million):	\$1
Float (million shares):	2
Short Interest (million shares):	~0
Dividend, annual (yield):	\$0 (NA%)

Revenues (US\$ million)

	<u>2025E</u> <u>(Cur.)</u>	<u>2025E</u> <u>(Old)</u>	<u>2026E</u> <u>(Cur.)</u>	<u>2026E</u> <u>(Old)</u>
Q1 Mar	0.4A	0.9E	0.5E	1.1E
Q2 Jun	0.4E	0.9E	0.5E	1.1E
Q3 Sep	0.4E	0.9E	1.0E	1.4E
Q4 Dec	<u>0.4E</u>	<u>0.9E</u>	<u>1.0E</u>	<u>1.4E</u>
Total	1.6E	3.6E	3.0E	5.0E
EV/Revs	0.6x		0.3x	

Earnings per Share (pro forma)

	<u>2025E</u> <u>(Cur.)</u>	<u>2025E</u> <u>(Old)</u>	<u>2026E</u> <u>(Cur.)</u>	<u>2026E</u> <u>(Old)</u>
Q1 Mar	(1.29)A	(0.71)E	(0.66)E	(0.59)E
Q2 Jun	(0.79)E	(0.73)E	(0.68)E	(0.61)E
Q3 Sep	(0.76)E	(0.70)E	(0.60)E	(0.55)E
Q4 Dec	<u>(0.74)E</u>	<u>(0.67)E</u>	<u>(0.58)E</u>	<u>(0.53)E</u>
Total	(3.44)E	(2.81)E	(2.51)E	(2.28)E
P/E	N/A		N/A	

Important Disclosures

Ascendant Capital Markets LLC seeks to do business with companies covered by its research team. Consequently, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making an investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report, beginning on page 12.

Exhibit 1: SINTX Investment Highlights (as of 2024)

SUMMARY

PORTFOLIO & EXPERTISE

SINTX holds a broad portfolio of advanced ceramics materials, with application across technical, antipathogenic, and medical market sectors. SINTX has unmatched global expertise in the development and application of silicon nitride, the premium portfolio offering.

EVOLVING

SINTX has fundamentally transformed over the past two years from a specialty materials company into an OEM that can serve many different markets with various product offerings that span significant ranges of quality, value, and economics.

INVEST

Invest at the inflection point as SINTX begins a new trajectory immediately post two acquisitions which set up the organization for long-term success

Focus Markets



Biomedical

- Used in over 40,000 human spine implantations
- Expanding with composites and coatings



Antipathogenic

- Antibacterial, antifungal, and antiviral applications
- Applications to PPE, filters, surfaces, coatings, wound care, catheters, wound drains, incontinence, and fem care



Industrial/Armor

- Able to withstand extreme conditions
- Used in aerospace, bearings, and drilling
- Personnel, aerospace, and vehicle protection

Source: Company reports.

Exhibit 2: SINTX's Silicon Nitride

SINTX Technologies Inc.

SINTX Technologies is a leading manufacturer of silicon nitride.

Silicon nitride...

- Is favorable to human cells and promotes bone fusion
- Discourages bacterial adhesion on its surface
- Inactivates viruses—including the SARS-CoV-2 virus

SINTX has investigated silicon nitride heavily, with over 130 peer-reviewed scientific papers and presentations.



STX-100

STX-100 silicon nitride has the best combination of mechanical, thermal, and electrical properties of any technical ceramic. Utilized when durability, thermal stability, exceptional strength, and wear resistance are required.



ENERGY



AUTOMOTIVE &
AEROSPACE BRAKES



AEROSPACE
MATERIALS




AUTOMOTIVE
CERAMICS



WELDING

Source: Company reports.

Exhibit 3: SINTX's Product Market Opportunity



Source: Company reports.

Exhibit 4: Silicon Nitride Antipathogenic, Biomedical, and Industrial Catalysts for Growth (as of 2024)

BIOMEDICAL

METAL COATINGS

Ceramic coatings for metal orthopedic and dental surgical implants and replacements. These coatings are targeted at overcoming the clinical limitations of metallic implants.

REGULATORY CLEARANCES FOR SPINAL IMPLANTS

Pursuing FDA clearance for SN-PEEK spinal fusion devices in the U.S. and similar clearances in OUS markets.

DENTAL

Working with dental implant companies to potentially supply novel silicon nitride and zirconia-based dental implants.

ABLATION TIPS

Quoting two global medical device companies for a significant volume of 3D printed bioceramic surgical ablation tips.

FOOT AND ANKLE

Leveraging success in spine market to attract interest from global leaders in this specialty area.

ANTIPATHOGENIC

AP FACE MASKS AND MASK FILTERS

Developing civil use antipathogenic face protection.

WOUND CARE

Evaluating antipathogenic wound dressings (bandages, surgical care) for reduced bacteria growth.

AUTOMOTIVE CABIN AIR FILTERS

Working with an automotive company on cabin air filters to reduce bacteria and virus.

MEDICAL TUBING COATINGS

Developing coatings for catheters and medical tubing aimed at reducing infections.

TECHNICAL CERAMICS

COMMERCIAL JETS

Working with two major companies on commercial jet ignition systems – silicon nitride is enabling.

WELDING COMPONENTS

In production: components for high-speed welding with an international OEM for automotive applications.

RF ANTENNAS

Working with several companies on RF antennas applications due to the excellent dielectric properties of silicon nitride.

CRITICAL APPLICATIONS

Engaged with many companies in evaluations of our materials in critical applications such as energy and defense.

ARMOR

The SLC ARMOR plant will start up in the 1st quarter 2023 with strong interest from potential customers.

GOVERNMENT CONTRACTS & GRANTS

NAVAL RESEARCH LABORATORY

Ultra hard materials for armor applications that supports power protection and war fighter protection in military generators and vehicles.

FUTURE GOVERNMENT CONTRACTS

Leverage 40 years and \$40+M in contracts and technical experience for future opportunities and innovations that can address market needs.

HIGH EFFICIENCY HEAT EXCHANGERS

Developed for high performance military equipment by the Office of Naval Research and Commercial HVAC systems for the Department of Energy.

DEFENSE ADVANCED RESEARCH PROJECTS AGENCY

CMC combustor for high heat temps.

MISSILE DEFENSE AGENCY

Extended life coatings for electrochemical machining tools.


GRANTS

In the last year, awarded three phase 1 grants from NIH totaling \$900K for 3D printed composite devices: spine implants, craniomaxillofacial implants, and trauma plates.

SINTX

Source: Company report.

Exhibit 5: SINTX Timeline



Source: Company report.

Exhibit 6: Q1 2025 and Recent Highlights (as of May 15, 2025)

SINTX Technologies Provides Business Update Highlighting Strategic Focus to Medical Device Commercialization

May 15, 2025 07:05 ET | Source: [SINTX Technologies, Inc.](#)

Follow

Salt Lake City, UT , May 15, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT), an advanced ceramics company pioneering medical and antipathogenic applications of silicon nitride (Si₃N₄), today provided a comprehensive update on its operational progress, strategic initiatives, and financial position for the first quarter ended March 31, 2025.

"We are executing a disciplined transformation that aligns our core capabilities in advanced ceramics with fast-growing, high-impact healthcare applications. This transition positions us for sustainable value creation," said Eric K. Olson, CEO and President of SINTX Technologies.

Refocusing on High-Growth Medical Markets

SINTX has accelerated its transition from a diversified industrial-ceramics business to a pure-play medical device innovator. Silicon nitride's proven biocompatibility, antimicrobial properties, and pro-regenerative properties uniquely position it for:

- Orthopedic implants
- Spinal fusion devices
- Dental products
- Medical Textiles including: wound care, surgical masks, sutures, drapes and other antipathogenic surfaces

This strategic redirection aims to address large, underserved clinical needs where infection resistance and osteogenesis and tissue healing are critical.

Technology & Market Development

Recent scientific and commercial initiatives include:

- New R&D programs targeting implantable and antipathogenic products
- An active technology pipeline focused on surgical-grade silicon nitride devices
- Partnerships and licensing discussions with leading medical OEMs
- SINTX's Salt Lake City facility remains only FDA-registered and ISO 13485 certified, silicon nitride ceramic manufacturer

Improved Financial Position

- \$6.5 million cash on hand as of March 31, 2025 – nearly doubling from \$3.6 million at year-end
- Recent \$5.0 million private placement in February 2025 supported strategic runway along with potential to raise an additional \$5.0 million dollars from the exercise of warrants with an exercise price of \$3.32 per share of common stock
- Reduced operating cash burn from \$2.7M in Q1 2024 to \$1.3M in Q1 2025 due to cost optimization

Operational Streamlining

- Sale of non-core subsidiary TA&T to Tethon Corporation
- Workforce reduction and shut down of underperforming Armor subsidiary
- Initiated negotiations to reduce long-term lease liabilities, particularly at the Armor facility

These actions are expected to further unlock capital for high-return growth projects.

Strengthened Governance and Leadership

In Q2, the Company welcomed a reconstituted Board of Directors with new appointments across all Board committees, reinforcing corporate oversight. In parallel, the Company entered into new long-term employment agreements with CEO Eric Olson and CIO Gregg Honigblum .

Path Forward


SINTX is now strategically aligned around:

- Expanding the use of silicon nitride in medical and antipathogenic markets
- Licensing and commercialization of proprietary technologies
- Select asset divestitures and disciplined capital investment
- Building long-term shareholder value through innovation and execution

"We are grateful for the support of our shareholders during this transformation. With a stronger balance sheet, a focused mission, and world-class technology, SINTX is well-positioned for a new era of innovation and impact in healthcare," Olson added.

Source: Company report.

Exhibit 7: SINTX Technologies, Inc. Stock Price (5-year)



*Reflects a 1:200 reverse stock split in May 2024

Source: <https://bigcharts.marketwatch.com/>

Exhibit 8: Consensus Expectations (as of May 15, 2025)

Revenue (mils)			EPS		
	2025E	2026E		2025E	2026E
Q1 Mar	\$0.6E		Q1 Mar	\$(0.80)E	
Q2 Jun	\$0.6E		Q2 Jun	\$(0.59)E	
Q3 Sep			Q3 Sep		
Q4 Dec			Q4 Dec		
Total	\$2.3E	\$2.1E	Total	\$(2.60)E	\$(1.76)E

*Quarterly estimates may not add to annual estimates due to variations in contributing estimates and rounding.

Source: Company report, LSEG, and Ascendant Capital Markets estimates

FINANCIAL MODEL

SINTX Technologies, Inc.

Income Statement (\$ mils)	Mar-23	Jun-23	Sep-23	Dec-23	2023	Mar-24	Jun-24	Sep-24	Dec-24	2024	Mar-25	Jun-25	Sep-25	Dec-25	2025	Mar-26	Jun-26	Sep-26	Dec-26	2026
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2E	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
Total Revenue	0.5	0.5	0.7	0.9	2.6	0.7	0.9	0.8	0.5	2.9	0.4	0.4	0.4	0.4	1.6	0.5	0.5	1.0	1.0	3.0
Cost of Revenues	0.4	0.3	0.5	0.6	1.9	0.5	0.6	0.7	0.4	2.1	0.3	0.3	0.3	0.3	1.1	0.3	0.3	0.7	0.7	2.0
Gross Profit	0.1	0.2	0.2	0.3	0.7	0.2	0.3	0.1	0.1	0.8	0.1	0.1	0.1	0.1	0.5	0.2	0.2	0.4	0.4	1.1
Research and development	2.2	2.1	2.5	1.8	8.7	2.0	1.7	0.8	0.7	5.2	1.1	1.0	1.0	1.0	4.1	1.0	1.0	1.0	1.0	4.0
Sales and marketing	0.3	0.3	0.3	0.3	1.1	0.2	0.3	0.1	0.0	0.6	0.2	0.1	0.1	0.1	0.5	0.1	0.1	0.1	0.1	0.4
General and administrative	1.2	1.2	1.0	0.9	4.2	1.1	1.1	0.8	1.0	4.0	1.2	1.1	1.1	1.1	4.5	1.1	1.1	1.1	1.1	4.4
Grant and contract expenses					0.0					0.0					0.0					0.0
Restructuring and other					0.0			4.9	0.1	5.0					0.0					0.0
Total operating expenses	3.7	3.6	3.8	3.0	14.1	3.4	3.0	6.5	1.9	14.8	2.5	2.2	2.2	2.2	9.1	2.2	2.2	2.2	2.2	8.8
Operating income (loss)	(3.6)	(3.5)	(3.6)	(2.7)	(13.4)	(3.2)	(2.7)	(6.4)	(1.7)	(14.0)	(2.4)	(2.1)	(2.1)	(2.1)	(8.6)	(2.0)	(2.0)	(1.9)	(1.9)	(7.8)
Interest income (expense)	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	(0.0)	(0.0)	(0.0)	0.0	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Other income (expense)	3.2	0.9	0.4	0.4	4.9	2.3	0.5	0.2	0.0	2.9	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.1
Income before income taxes	(0.3)	(2.5)	(3.2)	(2.3)	(8.3)	(0.9)	(2.2)	(6.2)	(1.7)	(11.0)	(2.3)	(2.1)	(2.1)	(2.1)	(8.5)	(1.9)	(2.0)	(1.9)	(1.9)	(7.7)
Income taxes					0.0					0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income (loss)	(0.3)	(2.5)	(3.2)	(2.3)	(8.3)	(0.9)	(2.2)	(6.2)	(1.7)	(11.0)	(2.3)	(2.1)	(2.1)	(2.1)	(8.5)	(1.9)	(2.0)	(1.9)	(1.9)	(7.7)
Nonrecurring/noncash adjustments					0.0					0.0					0.0					0.0
Net income (pro forma)	(0.3)	(2.5)	(3.2)	(2.3)	(8.3)	(0.9)	(2.2)	(6.2)	(1.7)	(11.0)	(2.3)	(2.1)	(2.1)	(2.1)	(8.5)	(1.9)	(2.0)	(1.9)	(1.9)	(7.7)
EBITDA																				
Shares, Basic	0.0	0.0	0.0	0.0	0.0	0.1	0.6	0.9	1.4	0.74	1.8	2.6	2.7	2.8	2.5	2.9	3.0	3.1	3.2	3.1
Shares, Diluted	0.0	0.0	0.0	0.0	0.0	0.2	0.7	0.9	1.4	0.74	1.8	2.6	2.7	2.8	2.5	2.9	3.0	3.1	3.2	3.1
EPS Basic (pro forma)	(\$22.91)	(\$111.84)	(\$151.61)	(\$110.31)	(\$443.47)	(\$10.26)	(\$3.49)	(\$6.96)	(\$1.26)	(\$14.87)	(\$1.29)	(\$0.79)	(\$0.76)	(\$0.74)	(\$3.44)	(\$0.66)	(\$0.68)	(\$0.60)	(\$0.58)	(\$2.51)
EPS Diluted (pro forma)	(\$22.91)	(\$111.84)	(\$145.02)	(\$77.37)	(\$380.29)	(\$5.14)	(\$3.16)	(\$6.95)	(\$1.26)	(\$14.80)	(\$1.29)	(\$0.79)	(\$0.76)	(\$0.74)	(\$3.44)	(\$0.66)	(\$0.68)	(\$0.60)	(\$0.58)	(\$2.51)
Margins																				
Gross margin	23%	31%	24%	30%	27%	28%	34%	18%	27%	27%	20%	35%	35%	35%	31%	35%	35%	35%	35%	35%
Research and development	408%	423%	372%	204%	332%	294%	195%	100%	131%	180%	302%	250%	250%	250%	262%	200%	200%	100%	100%	133%
Sales and marketing	58%	61%	38%	29%	43%	36%	30%	11%	5%	21%	49%	25%	25%	25%	31%	20%	20%	10%	10%	13%
General and administrative	217%	230%	146%	99%	161%	163%	125%	100%	185%	138%	314%	275%	275%	275%	284%	220%	220%	110%	110%	147%
Operating margin	-660%	-682%	-533%	-302%	-508%	-465%	-315%	-802%	-320%	-487%	-646%	-515%	-515%	-515%	-546%	-405%	-405%	-185%	-185%	-258%
Tax rate, GAAP	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Net margin	-54%	-488%	-471%	-257%	-315%	-129%	-257%	-781%	-313%	-382%	-621%	-516%	-516%	-516%	-540%	-386%	-406%	-185%	-185%	-255%
Y/Y % change																				
Total Revenue	318%	112%	59%	18%	68%	27%	69%	18%	-40%	10%	-46%	-53%	-50%	-26%	-46%	36%	25%	150%	150%	91%
Gross margin	149%	-8%	-53%	-63%	-45%	57%	84%	-12%	-46%	8%	-62%	-53%	-1%	-5%	-36%	143%	25%	150%	150%	113%
Research and development	33%	46%	66%	2%	35%	-8%	-22%	-68%	-61%	-40%	-45%	-40%	26%	41%	-21%	-10%	0%	0%	0%	-3%
Sales and marketing	-21%	-9%	-11%	-17%	-15%	-21%	-17%	-66%	-90%	-46%	-27%	-61%	15%	300%	-22%	-44%	0%	0%	0%	-16%
General and administrative	37%	18%	-7%	-17%	6%	-4%	-8%	-19%	12%	-5%	3%	3%	37%	10%	12%	-5%	0%	0%	0%	-1%
Operating income (loss)	24%	24%	29%	-5%	18%	-10%	-22%	77%	-36%	5%	-25%	-24%	-68%	19%	-39%	-15%	-2%	-10%	-10%	-9%
Net income (loss)	-90%	-1%	17%	-72%	-50%	202%	-11%	96%	-27%	33%	159%	-6%	-67%	22%	-23%	-16%	-2%	-10%	-10%	-10%
EPS Diluted (pro forma)	-99%	-94%	-93%	-98%	-96%	-78%	-97%	-95%	-98%	-96%	-75%	-75%	-89%	-41%	-77%	-49%	-15%	-22%	-21%	-27%

Source: Company reports and Ascendant Capital Markets estimates. *Reflects a 1-for-200 Reverse Stock Split in May 2024

SINTX Technologies, Inc.

Balance Sheet (\$ mils)	Mar-23	Jun-23	Sep-23	Dec-23	Mar-24	Jun-24	Sep-24	Dec-24	Mar-25	Jun-25	Sep-25	Dec-25	Mar-26	Jun-26	Sep-26	Dec-26
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1A	Q2E	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Assets																
Cash and cash equivalents	12.6	9.3	6.2	3.3	5.8	4.6	4.8	3.6	6.5	5.2	3.2	1.1	(0.2)	(2.1)	(2.5)	(4.1)
Short term investments										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts receivable, net	0.5	0.4	0.3	0.7	0.5	0.4	0.3	0.2	0.1	0.4	0.4	0.4	0.5	0.5	1.0	1.0
Inventory	0.4	0.7	0.8	0.9	0.7	0.4	0.5	0.5	0.4	0.2	0.2	0.2	0.2	0.2	0.4	0.4
Deferred income taxes										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Short-term note receivable										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaid expenses and other	0.8	0.7	0.6	0.6	0.6	0.4	0.7	0.5	0.6	0.6	0.6	0.6	0.7	0.7	1.4	1.4
Total current assets	14.3	11.1	7.9	5.5	7.5	5.9	6.3	4.8	7.6	6.4	4.4	2.2	1.2	(0.7)	0.4	(1.3)
Property and equipment, net	5.8	5.7	5.5	4.8	5.1	4.8	1.0	0.9	0.6	1.0	1.1	1.4	1.3	1.3	1.9	1.9
Intangibles, net	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred income tax										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Long-term note receivable										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Long-term inventory and other	2.3	2.3	2.1	5.0	5.0	4.6	3.9	3.7	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2
Total assets	22.7	19.1	15.5	15.4	17.6	15.3	11.3	9.4	11.4	10.6	8.7	6.8	5.8	3.9	5.6	3.9
Liabilities and stockholders' equity																
Accounts payable	0.5	0.5	0.5	0.6	0.4	0.3	0.2	0.3	0.4	0.7	0.7	0.7	0.9	0.9	1.8	1.8
Accrued expenses	1.5	1.5	1.7	1.4	2.0	1.6	1.1	1.0	1.2	1.9	1.9	1.9	2.4	2.4	4.9	4.9
Derivative liabilities	2.3	1.1	0.7	0.3	0.8	0.4	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Deferred revenue										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred income tax										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.8	0.8	0.8	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
Short term debt	0.1	0.1	0.1	0.0	0.2	0.2	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Total current liabilities	5.1	3.9	3.8	2.9	4.1	3.0	2.1	2.0	2.2	3.3	3.3	3.3	3.9	3.9	7.3	7.3
Deferred income taxes										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Warrant liabilities										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other long term liabilities	1.5	1.3	1.0	3.7	3.5	3.4	3.6	3.5	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1
Long term debt	0.0	0.0								0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total other liabilities	1.6	1.4	1.0	3.7	3.5	3.4	3.6	3.5	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1
Preferred stock																
Common stock	0.0	0.0	0.0	0.1	0.5	0.0	0.0	0.0	0.0	0.2	0.4	0.6	0.7	0.9	1.1	1.3
Additional paid-in capital	278.7	279.0	279.0	279.4	281.0	282.6	285.6	285.6	290.1	290.1	290.1	290.1	290.1	290.1	290.1	290.1
Retained earnings	(262.7)	(265.2)	(268.4)	(270.7)	(271.6)	(273.8)	(280.0)	(281.7)	(284.0)	(286.1)	(288.2)	(290.2)	(292.1)	(294.2)	(296.0)	(297.9)
Accumulated other comprehensive income										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total stockholders' equity	15.9	13.8	10.7	8.8	9.9	8.8	5.6	3.9	6.1	4.2	2.3	0.4	(1.3)	(3.2)	(4.8)	(6.5)
Total stockholders' equity and liabil	22.7	19.1	15.5	15.4	17.6	15.3	11.3	9.4	11.4	10.6	8.7	6.8	5.8	3.9	5.6	3.9

Balance Sheet Drivers

	Mar-23	Jun-23	Sep-23	Dec-23	Mar-24	Jun-24	Sep-24	Dec-24	Mar-25	Jun-25	Sep-25	Dec-25	Mar-26	Jun-26	Sep-26	Dec-26
	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1A	Q2E	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Prepaid as % of total rev	150%	136%	86%	69%	82%	49%	89%	88%	161%	140%	140%	140%	140%	140%	140%	140%
Accounts payable as % of total rev	90%	99%	71%	71%	65%	39%	19%	55%	119%	177%	177%	177%	177%	177%	177%	177%
Inventories as % of cost of rev	93%	200%	164%	141%	143%	79%	70%	127%	143%	64%	64%	64%	64%	64%	64%	64%
Accrued expenses as % of total rev	279%	297%	258%	156%	297%	181%	138%	182%	315%	487%	487%	487%	487%	487%	487%	487%
Activity Ratios																
A/R Days Sales Outstanding	78	68	34	68	63	45	38	33	24	93	93	93	93	93	93	93
Inventory Turnover	4.3x	2.0x	2.4x	2.8x	2.8x	5.1x	5.7x	3.1x	2.8x	6.3x	6.3x	6.3x	6.3x	6.3x	6.3x	6.3x
A/P Days Payable	105	130	84	91	81	53	21	68	133	245	245	245	245	245	245	245
Book & Cash Value (per share)																
Book Value per Share (diluted)	#####	#####	485.94	#####	57.61	12.68	6.22	2.88	3.44	1.62	0.86	0.16	(0.45)	(1.06)	(1.56)	(2.04)
Cash per Share (diluted)	987.15	#####	282.73	#####	33.44	6.53	5.36	2.67	3.67	2.01	1.20	0.39	(0.06)	(0.70)	(0.80)	(1.28)
Net cash per Share (diluted)	975.43	#####	279.46	#####	32.09	6.18	5.21	2.64	3.59	1.95	1.15	0.35	(0.11)	(0.74)	(0.84)	(1.32)

Source: Company reports and Ascendant Capital Markets estimates

SINTX Technologies, Inc.


Cash Flow Statement (\$ mils)	Mar-23	Jun-23	Sep-23	Dec-23	2023	Mar-24	Jun-24	Sep-24	Dec-24	2024	Mar-25	Jun-25	Sep-25	Dec-25	2025	Mar-26	Jun-26	Sep-26	Dec-26	2026
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2E	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
Cash flow from operating activities																				
Net income	(0.3)	(2.5)	(3.2)	(2.3)	(8.3)	(0.9)	(2.2)	(6.2)	(1.7)	(11.0)	(2.3)	(2.1)	(2.1)	(2.1)	(8.5)	(1.9)	(2.0)	(1.9)	(1.9)	(7.7)
Depreciation	0.2	0.2	0.3	0.3	0.9	0.3	0.3	0.2	0.1	0.8	0.1	0.1	0.1	0.1	0.4	0.1	0.1	0.1	0.1	0.4
Amortization	0.2	0.2	0.2	0.2	0.8	0.2	0.1	0.1	0.1	0.5	0.1				0.1					0.0
Debt related amortization expense					0.0					0.0					0.0					0.0
Stock comp	0.1	0.1	0.1	0.1	0.3	0.1	0.0	0.0	0.0	0.1	0.2	0.2	0.2	0.2	0.7	0.2	0.2	0.2	0.2	0.7
Bad debt expense	(0.0)	0.0	0.0	0.1	0.1	0.0	(0.0)	0.0	(0.0)	0.0	(0.0)				(0.0)					0.0
Inventory reserve			0.1	(0.1)	0.0					0.0					0.0					0.0
Deferred income taxes					0.0					0.0					0.0					0.0
Change in fair value of warrant l	(3.9)	(1.0)	(0.4)	(0.4)	(5.6)	(2.8)	(0.4)	(0.2)	(0.0)	(3.5)	(0.1)				(0.1)					0.0
Writedowns and impairments					0.0			4.5	0.1	4.6	0.1				0.1					0.0
Other gains/losses			(0.0)		(0.0)		(0.0)	0.0	0.0	0.0	0.0				0.0					0.0
Other					0.0					0.0					0.0					0.0
Changes in operating assets and liabilities:																				
Accounts receivable	(0.1)	0.1	0.1	(0.4)	(0.4)	0.2	0.1	0.1	0.2	0.5	0.0	(0.3)	0.0	0.0	(0.3)	(0.1)	0.0	(0.5)	0.0	(0.6)
Inventory	0.1	(0.3)	(0.2)	(0.2)	(0.5)	0.0	0.2	(0.0)	(0.1)	0.1	0.1	0.3	0.0	0.0	0.3	(0.0)	0.0	(0.2)	0.0	(0.2)
Prepaid expenses & other curre	(0.5)	0.1	0.1	(0.0)	(0.3)	0.3	0.2	(0.3)	0.2	0.5	0.0	0.0	0.0	0.0	0.1	(0.1)	0.0	(0.7)	0.0	(0.8)
Income tax					0.0					0.0					0.0					0.0
Other assets					0.0					0.0					0.0					0.0
Accounts payable	(0.1)	(0.0)	0.3	(0.2)	(0.0)	0.1	(0.3)	(0.6)	0.0	(0.8)	0.6	0.3	0.0	0.0	0.8	0.2	0.0	0.9	0.0	1.1
Accrued expenses	(0.2)	(0.2)	(0.0)		(0.4)					0.0		0.8	0.0	0.0	0.8	0.5	0.0	2.4	0.0	2.9
Deferred revenue					0.0					0.0					0.0					0.0
Other liabilities	(0.3)	(0.0)	(0.2)	(0.1)	(0.7)	(0.1)	(0.1)	(0.1)	(0.1)	(0.5)	(0.1)	0.0	0.0	0.0	(0.1)	0.0	0.0	0.0	0.0	0.0
Net cash (used in) provided by	(4.871)	(3.200)	(2.916)	(3.128)	(14.115)	(2.7)	(2.2)	(2.6)	(1.1)	(8.6)	(1.3)	(0.8)	(1.8)	(1.8)	(5.6)	(1.3)	(1.8)	0.3	(1.6)	(4.3)
Cash flow from investing activities																				
Purchases of property and equi	(0.2)	(0.1)	(0.1)	(0.1)	(0.5)	(0.2)	(0.4)	(0.0)	(0.1)	(0.7)	(0.1)	(0.5)	(0.2)	(0.4)	(1.1)	(0.0)	(0.1)	(0.7)	(0.1)	(0.9)
Purchases of short-term investments					0.0					0.0					0.0					0.0
Acquisitions					0.0					0.0					0.0					0.0
Other				0.0	0.0	0.0	0.4	(0.0)	0.2	0.5	(0.0)				(0.0)					0.0
Net cash used in investing activ	(0.2)	(0.1)	(0.1)	(0.1)	(0.5)	(0.2)	0.0	(0.0)	0.0	(0.2)	(0.1)	(0.5)	(0.2)	(0.4)	(1.1)	(0.0)	(0.1)	(0.7)	(0.1)	(0.9)
Cash flow from financing activities																				
Issuance of debt	4.8			1.8	6.7					0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Repayment of debt	(0.0)		(0.1)	(0.0)	(0.1)	(0.0)	(0.1)	(0.1)	(0.1)	(0.3)					0.0					0.0
Issuance of stock					0.0	2.0	1.1	3.0	0.0	6.1	4.4	0.0	0.0	0.0	4.4	0.0	0.0	0.0	0.0	0.0
Proceeds from stock option exe	6.7			(1.5)	5.2	3.4	0.0	0.0	0.0	3.4					0.0					0.0
Other					0.0					0.0	(0.1)				(0.1)					0.0
Dividends and distributions					0.0					0.0					0.0					0.0
Cash provided by (used in) fina	11.5	0.0	(0.1)	0.3	11.7	5.3	1.0	2.9	(0.1)	9.1	4.3	0.0	0.0	0.0	4.3	0.0	0.0	0.0	0.0	0.0
Effect of exchange rate on cash					0.0					0.0					0.0					0.0
Net increase (decrease) in cash	6.4	(3.3)	(3.1)	(2.9)	(2.9)	2.4	(1.2)	0.3	(1.2)	0.3	2.9	(1.3)	(2.0)	(2.1)	(2.5)	(1.3)	(1.9)	(0.4)	(1.6)	(5.2)
Beginning cash and equivalents	6.2	12.6	9.3	6.2	6.2	3.3	5.8	4.6	4.8	3.3	3.6	6.5	5.2	3.2	3.6	1.1	(0.2)	(2.1)	(2.5)	1.1
Ending cash and equivalents	12.6	9.3	6.2	3.3	3.3	5.8	4.6	4.8	3.6	3.6	6.5	5.2	3.2	1.1	1.1	(0.2)	(2.1)	(2.5)	(4.1)	(4.1)

Source: Company reports and Ascendant Capital Markets estimates

ANALYST CERTIFICATION

Each analyst hereby certifies that the views expressed in this report reflect the analyst's personal views about the subject securities or issuers. Each analyst also certifies that no part of the analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The analyst who prepared this report is compensated based upon the overall profitability of Ascendant Capital Markets, LLC, which may, from time to time, include the provision of investment banking, financial advisory and consulting services. Compensation for research is based on effectiveness in generating new ideas for clients, performance of recommendations, accuracy of earnings estimates, and service to clients.

SINTX Technologies, Inc.



*Reflects a 1:200 reverse stock split in May 2024

Source: <https://bigcharts.marketwatch.com/>

	Report Date		Price	
Report	Date	Rating	Target	
1	9/11/2019	Buy	60,000	
2	11/15/2019	Buy	65,000	
3	4/4/2020	Buy	50,000	
4	5/16/2020	Buy	45,000	
5	8/21/2020	Buy	80,000	
6	11/21/2020	Buy	85,000	
7	3/31/2021	Buy	90,000	
8	5/21/2021	Buy	95,000	
9	8/25/2021	Buy	90,000	
10	11/16/2021	Buy	70,000	
11	4/13/2022	Buy	65,000	
12	6/1/2022	Buy	55,000	
13	8/16/2022	Buy	50,000	
14	11/18/2022	Buy	40,000	
15	4/4/2023	Buy	8,000	
16	5/30/2023	Buy	3,000	
17	8/9/2023	Buy	2,000	
18	4/29/2024	Buy	300	
19	5/31/2024	Buy	70	
20	4/18/2025	Buy	30	

- Ascendant Capital Markets, LLC has received compensation for advisory or investment banking services from the company in the past 12 months.

IMPORTANT DISCLOSURES

This report has been distributed by Ascendant Capital Markets, LLC and is for the sole use of our clients. This report is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. This report contains information from various sources, including United States government publications, The Wall Street Journal and other periodicals, Yahoo! Finance and other sources, and is for informational purposes only and is not a recommendation to trade in the securities of the companies mentioned within the report. We seek to update our research and recommendations as appropriate, but the large majority of reports are published at irregular intervals as we consider appropriate and, in some cases, as constrained by industry regulations.

We may have a business relationship with companies covered in this report. Ascendant Capital Markets, LLC may make a market in the securities of the subject company. We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this report. This report is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any information in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of the investments referred to in this report may fluctuate.

Following are some general risks that can adversely impact future operational and financial performance and share price valuation: (1) industry fundamentals with respect to legislation, mandates, incentives, customer demand, or product pricing; (2) issues relating to competing companies or products; (3) unforeseen developments with respect to management, financial condition or accounting policies or practices; or (4) external factors that affect the interest rates, currency, the economy or major segments of the economy. Past performance is not a guide to future performance, future returns are not guaranteed, and loss of original capital may occur. Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Our report is disseminated primarily electronically, and, in some cases, in printed form. The information contained in this report is not incorporated into the contents of our website and should be read independently thereof. Copyright Ascendant Capital Markets, LLC. No part of this material may be copied, photocopied or duplicated by any means or redistributed without the prior written consent of Ascendant Capital Markets, LLC.

Risks & Considerations

Risks to attainment of our share price target include balance sheet/liquidity risks, failure of product candidates to demonstrate safety and efficacy in clinical trials/studies, failure to gain/maintain regulatory approvals, ability to commercialize product, failure to obtain suitable reimbursement, competition, changing macroeconomic factors, investor sentiment for investing in biotech/medtech stocks, and changes in consumer or government priorities for healthcare.

Ascendant Capital Markets, LLC Rating System

BUY: We expect the stock to provide a total return of 15% or more within a 12-month period.

HOLD: We expect the stock to provide a total return of negative 15% to positive 15% within a 12-month period.

SELL: We expect the stock to have a negative total return of more than 15% within a 12-month period.

Total return is defined as price appreciation plus dividend yield.

Ascendant Capital Markets, LLC Distribution of Investment Ratings (as of April 11, 2025)

Rating	Count	Percent	Investment Banking Services Past 12 months	
			Count	Percent
Buy	52	98%	21	40%
Hold	0	0%	0	0%
Sell	1	2%	0	0%
Total	53	100%	21	40%

Other Important Disclosures

Our analysts use various valuation methodologies including discounted cash flow, price/earnings (P/E), enterprise value/EBITDAS, and P/E to growth rate, among others. Risks to our price targets include failure to achieve financial results, product risk, regulatory risk, general market conditions, and the risk of a change in economic conditions.

Dissemination of Research

Ascendant Capital Markets, LLC research is distributed electronically via the Thomson Reuters platforms, Bloomberg, Capital IQ and FactSet. Please contact your investment advisor or institutional salesperson for more information.

General Disclaimer

The information and opinions in this report were prepared by Ascendant Capital Markets, LLC. This information is not intended to be used as the primary basis of investment decisions and because of individual client objectives it should not be construed as advice designed to meet the particular investment needs of any investor. This material is for information purposes only and is not an offer or solicitation with respect to the purchase or sale of any security. The reader should assume that Ascendant Capital Markets, LLC may have a conflict of interest and should not rely solely on this report in evaluating whether or not to buy or sell securities of issuers discussed herein. The opinions, estimates, and projections contained in this report are those of Ascendant Capital Markets, LLC as of the date of this report and are subject to change without notice. Ascendant Capital Markets, LLC endeavors to ensure that the contents have been compiled or derived from sources that we believe are reliable and contain information and opinions that are accurate and complete. However, Ascendant Capital Markets, LLC makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions contained herein, and accepts no liability whatsoever for any loss arising from any use of, or reliance on, this report or its contents. Information may be available to Ascendant Capital Markets, LLC, or its affiliates that is not reflected in this report. This report is not to be construed as an offer or solicitation to buy or sell any security.

Additional Disclosures

Ascendant Capital Markets, LLC is a broker-dealer registered with the United States Securities and Exchange Commission (SEC) and a member of the FINRA and SIPC. Ascendant Capital Markets, LLC is not a Registered Investment Advisor nor is it an investment advisor registered with the Securities and Exchange Commission or with the securities regulators of any state, and at the present time is not eligible to file for federal registration.